Reports of Medicare Advantage (MA) patients receiving higher-quality care for their cardiovascular disease prompted this comparison study of patients with heart failure enrolled in Medicare fee-for-service plans (FFS) and MA plans.
Reports of Medicare Advantage (MA) patients receiving higher-quality care for their cardiovascular disease prompted an observational, retrospective, cohort study of MA patients with heart failure and their fee-for-service (FFS) enrollee counterparts. The results, published in JAMA Cardiology, show that mortality and the quality of care in both patients groups were consistent for those hospitalized for heart failure.
One-third of Medicare beneficiaries are enrolled in MA plans, the private insurance option for plan participants.
The primary outcomes of the study were in-hospital mortality, discharge disposition, length of stay (LOS) 4 days or less, and 4 heart failure achievement measures for 262,626 patients enrolled in the Get With the Guidelines-Heart Failure (GWTG-HF) registry:
For the 2 groups (MA = 35.6% [93,549]; FFS = 64.4% [169,077]), overall results show that standardized mean differences were less than 10% for age, sex, comorbidities, or objective measures (eg, vital signs, lab values) and for all heart failure achievement measures. Median (interquartile range [IQR]) age was also similar in the groups, at 78 (IQR, 70-85) years for MA enrollees and 78 (IQR, 69-86) years for FFS members.
All patients included in the study had to be 18 years or older; have heart failure; and have Medicare insurance coverage between January 1, 2014, and December 31, 2018; and list FFS Medicare or MA as their only source of payment.
However, discharge to home was more likely to happen for patients in MA vs FFS plans (adjusted odds ratio [aOR], 1.16; 95% CI, 1.13-1.19; P < .001), and they had a lower odds of hospital discharge within 4 days (AOR, 0.97; 95% CI, 0.93-1.00; P = .04). Mortality remained consistent (aOR, 0.98; 95% CI, 0.92-1.03; P = .42) between the groups.
Further analysis produced these results for patients in MA vs FFS plans:
Overall mortality was just 2.9% for MA enrollees and 3.0% (P = .05) for FFS enrollees.
“Among patients hospitalized with heart failure, no observable benefit was noted in quality of care or in-hospital mortality between those enrolled in MA vs FFS Medicare, except lower use of post–acute care facilities,” the authors concluded. “As MA continues to grow, it will be important to ensure that participating private plans provide an added value to the patients they cover to justify the higher administrative costs compared with traditional FFS Medicare.”
Study limitations that may restrict generalization of their findings are that hospital participation in the GWTG-HF registry is voluntary, which means those not participating could differ as could their patient demographics; the GWTG-HF registry does not contain data on patient social determinants of health; and not all patients enrolled in MA or FFS Medicare were included in the analysis.
Reference
Figueroa JF, Wadhera WK, Frakt, AB, et al. Quality of care and outcomes among Medicare Advantage vs fee-for-service Medicare patients hospitalized with heart failure. JAMA Cardiol. Published online September 2, 2020. doi:10.1001/jamacardio.2020.3638
Employers Shift to Equity-Focused Strategies as Health Costs Outpace Wages
October 31st 2024As health care costs escalate, a new survey reveals that 74% of employers are grappling with the impact on employee wages and benefits, with many anticipating further cost-shifting to their workforce.
Read More
Frameworks for Advancing Health Equity: Health Equity by Design
July 23rd 2024Melissa Clarke, MD, CMQ, the chief health equity officer at Elevance Health, explains "Health Equity by Design" and how Elevance Health is committed to ensuring a personalized and intentional approach for all its members.
Listen
Nathan Walcker Discusses Value-Based Oncology Care Initiatives at FCS
September 8th 2023Nathan Walcker, CEO at Florida Cancer Specialists & Research Institute (FCS), highlights some of the recent partnerships and initiatives at FCS to improve community-based oncology care from a value-based perspective.
Listen
Ways Providers, Payers Can Ensure Biomarker Testing Is Done in Cancer Care
October 18th 2024There is a role for both payers and providers to make small changes that would increase the use of biomarker testing to ensure patients are receiving the appropriate treatment, said Susan Wescott, RPh, MBA, senior director of managed care pharmacy, Mayo Clinic.
Read More